AlphaMadera's AlphaVal page computes Leggett & Platt, Incorporated's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag LEG as undervalued, fairly valued, or overvalued.

What is Leggett & Platt, Incorporated's fair value?

Fair value for LEG is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value LEG?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from LEG's most recent reported fundamentals.

LEG - Leggett & Platt, Incorporated

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $12.00 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Undervalued Strong

Trading 61.4% below fair value

Current Price $9.99

Bear Case $22.63 126.5% upside ($22.63 - $9.99) / $9.99 = 126.5% $1.83 × 14x P/E

Fair Value $25.86 158.8% upside ($25.86 - $9.99) / $9.99 = 158.8% $1.83 × 16x P/E

Bull Case $29.09 191.2% upside ($29.09 - $9.99) / $9.99 = 191.2% $1.83 × 18x P/E

Adjust Assumptions

P/E Multiple

16.0x

Adjusted EPS

1.83$

Key Value Driver

Normalized P/E multiple (16x base case)

Implied Market Multiple 5.5x

Plain-Language Summary

Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $12.00 from 14 analysts, using a 20% weight on analyst consensus. That produces an estimated intrinsic value of $25.86 per share.

Warnings

ℹ Wall Street's average price target is $12.00 (from 14 analysts). Our estimate is 144% above the consensus -- consider that gap carefully.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples